Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 | P11387 | 13/20 | 0.61 |
| ▸ | CDK4 | P11802 | 4/20 | 0.44 |
| ▸ | CCND1 | P24385 | 4/20 | 0.44 |
| ▸ | PRKCQ | Q04759 | 3/20 | 0.42 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.41 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | PRKACA | P17612 | 1/20 | 0.41 |
| ▸ | PRKACG | P22612 | 1/20 | 0.41 |
| ▸ | PRKACB | P22694 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5870296 | 0.88 | TOP1 (0.60) | TOP1CDK4CCND1PRKCQCCNE2 | |
| SCHEMBL5869634 | 0.82 | TOP1 (0.51) | TOP1CDK4CCND1PRKCQCCNE2 | |
| SCHEMBL5666509 | 0.82 | TOP1 (0.69) | TOP1CDK4CCND1PRKCQCCNE2 | |
| SCHEMBL5666540 | 0.79 | TOP1 (0.75) | TOP1CDK4CCND1PRKCQCCNE2 | |
| SCHEMBL7025632 | 0.79 | TOP1 (0.75) | TOP1CDK4CCND1PRKCQCCNE2 | |
| SCHEMBL14440435 | 0.78 | TOP1 (0.63) | TOP1CDK4CCND1PRKCQCCNE2 | |
| SCHEMBL5869886 | 0.76 | TOP1 (0.60) | TOP1CDK4CCND1PRKCQCCNE2 | |
| SCHEMBL5664777 | 0.76 | TOP1 (1.00) | TOP1 | |
| SCHEMBL6727359 | 0.76 | TOP1 (1.00) | TOP1PRKCQ | |
| SCHEMBL29489909 | 0.76 | TOP1 (1.00) | TOP1PRKCQ |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6653290-B2 | Sugar derivatives of indolocarbazoles; exhibit topoisomerase-I activity | BRISTOL-MYERS SQUIBB COMPANY | 2003-11-25 | — | — | US | disclosed |
| US-20020068705-A1 | Tumor proliferation inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2002-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020068705-A1 | Tumor proliferation inhibitors | MKI67, TOP1, CCNI | TOP1 2/4885CDK4 19/4885CCND1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.